Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** 3. Record review for R14 revealed the resident was admitted to the facility on [DATE] with a diagnosis of, but not limited to, bipolar disorder.
Review of the admission MDS dated [DATE] revealed Section A (Identification Information) documented the resident had not been evaluated by Level II PASRR and determined to have a serious mental illness and/or mental retardation or a related condition. Section I (Active Diagnoses) documented manic depression (bipolar disease) as a diagnosis.
Review of the Quarterly Minimum Data Set (MDS) dated [DATE] revealed Section C (Cognitive Pattern) documented a BIMS of 12 (indicating moderate cognitive impairment). Section I (Active Diagnoses) documented manic depression (bipolar disease) as a diagnosis.
Review of R14's medications revealed the resident was currently prescribed clonazepam 1 mg by mouth two times daily for anxiety, quetiapine fumarate 100 mg one tablet by mouth every morning and at bedtime for bipolar, and sertraline HCL 75 mg one tablet by mouth one time a day for depression.
Review of R14's PASRR Level I assessment dated [DATE] revealed R14 did not have a primary diagnosis of dementia, did not have a terminal illness, and did not have a diagnosis of a serious mental illness or mental disorder.
Further review of R14's EMR revealed a diagnosis of bipolar disorder that was initiated on 4/2/2024 with no indication of a PASRR Level II submission on behalf of R14.
Review of the Progress Notes located in the EHR revealed an entry dated 3/30/3034 at 9:24 pm that R14 exhibited screaming constantly, crying, and hallucinations.
Review of the Behavioral Monitoring document for R14 indicated that resident exhibited behavioral symptoms six of 31 days in January 2025 (1/13/2025, 1/15/2025,1/20/2025, 1/21/2025 1/29/2025 and 1/31/2025) and 12 of 28 days in February 2025 (2/1/2025, 2/3/2025, 2/6/2025, 2/7/2025, 2/11/2025, 2/13/2025, 2/13/2025, 2/17/2025,2/18/2025, 2/20/2025, 2/21/2025, 2/27/2025, and 2/28/2025).
Review of the facility-provided list of residents with Level II PASRR within the facility revealed that R14's name was not listed.
Observation on 3/14/2025 at 2:35 pm revealed R14 was yelling out help, help. There was staff in the resident's room providing care to other residents.
Observation on 3/15/2025 at 8:31 am and 10:31 am revealed R14 lying in bed, yelling inaudible words.
Observation on 3/15/2025 at 5:29 pm revealed R14 was yelling out help repeatedly. The staff was passing dinner trays to other residents.
In an interview on 3/15/2025 at 5:43 pm, the Regional Nurse Consultant confirmed that R14 only had a Level I PASRR, and a PASRR Level II had not been applied for.
4. Review of the medical record for R294 revealed the resident was admitted with the diagnoses of, but not limited to, major depressive disorder, anxiety disorder, and bipolar disorder.
Review of the admission MDS dated [DATE] revealed Section A (Identification Information) documented the resident had not been evaluated by Level II PASRR and determined to have a serious mental illness and/or mental retardation or a related condition.
Review of the Quarterly Minimum Data Set (MDS) dated [DATE] revealed Section C (Cognitive Patterns) revealed a Brief Interview For Mental Status score of 14 (indicating little to no cognitive impairment). Section I (Active Diagnoses) documented diagnoses of anxiety disorder, depression, and bipolar disorder.
Review of R294's medication regime revealed the resident was prescribed citalopram 30 mg, one tablet by mouth daily (a medication used to treat depression), and quetiapine fumarate 50 mg, one tablet by mouth two times a day for bipolar disorder.
Review of R294's PASRR Level I assessment dated [DATE] revealed R5 did not have a primary diagnosis of dementia, did not have a terminal illness, and did not have a diagnosis of a serious mental illness or mental disorder.
Review of R294's EHR revealed a diagnosis of bipolar disorder that was initiated on 4/2/2024 with no indication that a PASRR Level II was applied for on behalf of R294.
Review of the Behavioral Monitoring document for R294 revealed that the resident exhibited behavioral symptoms two of 31 days in January 2025 (1/19/2025 and 1/27/2025) and four of 28 days in February (2/4/2025, 2/10/2025, 2/11/2025, and 2/12/2025).
Review of the facility-provided list of residents with Level II PASRR within the facility revealed that R294's name was not listed.
In an interview on 3/15/2025 at 5:43 pm, the Regional Nurse Consultant confirmed that R294 only had a Level I PASRR, and a PASRR Level II had not been applied for.
Based on observations, staff interviews, record review, and review of the facility's policy titled, Resident Assessment-Coordination with PASARR Program, the facility failed to submit for a Preadmission Screening and Resident Review (PASRR) Level II after a new mental illness diagnosis was added for four of 35 sampled residents (R) (R5, R2, R14, and R294) reviewed for PASRR. This deficient practice had the potential to place R5, R2, R14, and R294 at risk of not receiving services and/or care according to their needs.
Findings include:
Review of the facility's policy titled, Resident Assessment-Coordination with PASARR Program, dated 3/1/2022, revealed the section titled Policy Explanation and Compliance Guidelines included . 6. The Social Services Director shall be responsible for keeping track of each resident's PASARR screening status and referring to the appropriate authority .9. Any resident who exhibits a newly evident or possible serious mental disorder, intellectual disability, or a related condition will be referred promptly to the state mental health or intellectual disability authority for a level II resident review. Examples include: (b) A resident whose intellectual disability or related condition was not previously identified and evaluated through PASARR.
1. Review of the admission Record revealed R5 was admitted to the facility on [DATE] with diagnoses that included, but not limited to, unspecified dementia of unspecified severity without behavioral disturbance, psychotic disturbance, mood disturbance, anxiety, and Post-Traumatic Stress Disorder (PTSD). Depression was added as a diagnosis on 11/6/2023.
Review of R5's Annual Minimum Data Set (MDS) dated [DATE] Section A (Identification Information) documented the resident had not been evaluated by Level II PASRR and determined to have a serious mental illness and/or mental retardation or a related condition. Section C (Cognitive Patterns) revealed a Brief Interview for Mental Status (BIMS) score of eight (indicating moderate cognitive impairment). Section I (Active Diagnosis) revealed non-Alzheimer's dementia, depression (other than bipolar), and PTSD. Section N (Medications) revealed the resident received antidepressant medications during the look-back period of the assessment. Section O (Special Treatments, Procedures, and Programs) revealed no psychological therapy during the look-back period of the assessment.
Review of R5's Physician Orders, dated 10/4/2023, revealed the resident was currently receiving sertraline hydrochloride (HCL) tablet 75 milligrams (mg) by mouth one time a day for depression.
Review of R5's PASRR Level I assessment dated [DATE] revealed R5 did not have a primary diagnosis of dementia, did not have a terminal illness, and did not have a diagnosis of a serious mental illness or mental disorder.
Further review of R5's electronic health records (EHR) revealed no submissions for a PASRR Level II after the new mental illness diagnoses were added.
Review of the facility-provided list of residents with Level II PASRR within the facility revealed that R5's name was not listed.
In an interview on 3/15/2025 at 5:00 pm, the Regional Nurse Consultant confirmed R5 did not have a PASRR Level II. She stated that R5 qualified as a PASRR Level I and provided the PASRR Level I screen.
2. Review of the admission Record revealed that R2 was admitted to the facility on [DATE] with diagnoses that included, but not limited to, depression, PTSD, anxiety disorder and unspecified dementia, unspecified severity (all added on 4/26/2024), adjustment disorder with mixed anxiety and depressed mood added on 8/27/2024, and delusional disorder added on 5/14/2024.
Review of R2's Annual MDS dated [DATE] Section A (Identification Information) documented the resident had not been evaluated by Level II PASRR and determined to have a serious mental illness and/or mental retardation or a related condition. Section C ( Cognitive Patterns) revealed a BIMS score of 13 (indicating little to no cognitive impairment). Section I (Active Diagnosis) revealed anxiety disorder, depression (other than bipolar), and PTSD. Section N (Medications) revealed the resident received antipsychotics, antidepressants, and opioid medications during the look-back period of the assessment. Section O (Special Treatments, Procedures, and Programs) revealed no psychological therapy during the look-back period of the assessment.
Review of R2's Physician Orders, dated 2/7/2025, revealed the resident was currently receiving fluoxetine HCL oral capsule 20 mg, two capsules by mouth one time a day for depression, and quetiapine fumarate oral tablet 100 mg, one tablet by mouth at bedtime for delusional disorder.
Review of R2's PASRR Level I assessment dated [DATE] revealed R2 did not have a primary diagnosis of dementia and had a serious mental illness or mental disorder of depression.
Further review of R2's EHR revealed no submissions for a PASRR Level II after the new mental illness diagnoses were added.
Review of the facility-provided list of residents with Level II PASRR within the facility revealed that R2's name was not listed.
In an interview on 3/16/2025 at 11:32 am, the Director of Operations (DOO) and MDS Director HH reviewed R5 and R2's EHRs. MDS Director HH confirmed R5 and R2 had documented qualifying diagnosis for a PASRR Level II, and a PASRR Level I screen had not been resubmitted after R5 and R2 received the new diagnoses. The DOO revealed that they had a new Social Services Director (SSD) at the facility who was being trained. She stated she expected staff to resubmit the PASRR Level I screenings if qualifying diagnoses were added.
In a telephone interview on 3/16/2025 at 11:43 am, the SSD revealed she was new in her role but was responsible for submitting PASRRs. She revealed that she had only worked in the facility for one week and was currently training with MDS Director HH. She stated that she had no knowledge of R2 or R5's diagnoses or PASRR status and was still learning the process.